Steven H Lin1, Heather Y Lin2, Vivek Verma3, Meng Xu-Welliver4, Peter F Thall2, Luyang Yao3, Peter Y Kim5, Dan S Gombos6, Jitesh D Kawedia7, Ritsuko Komaki3, Daniel R Gomez3, Quynh-Nhu Nguyen3, Michael S O'Reilly3, Charles Lu8, Frank V Fossella8, Ferdinandos Skoulidis8, Jianjun Zhang8, Anne S Tsao8, John V Heymach8, George R Blumenschein8. 1. Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: shlin@mdanderson.org. 2. Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 3. Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 4. Department of Radiation Oncology, Ohio State University, Columbus, OH, USA. 5. Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 6. Department of Ophthalmology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 7. Clinical Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 8. Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung cancer (NSCLC). METHODS: Patients received cCRT (carboplatin/paclitaxel and 60 Gy/30 fractions radiotherapy); oral trametinib (7 days/week) commenced on day 1 and completed on the final day of radiotherapy. Dose-finding of trametinib was done using the time-to-event continual reassessment method (TiTE-CRM); dose levels were 0.5mg (level -1), 1mg (initial, level 1), 1.5mg (level 2), and 2mg (level 3). Progression-free (PFS) and overall survival (OS) times were also recorded. RESULTS: Fifteen patients (stage III, variety of KRAS mutations) were treated, with 1/5/4/5 at dose levels -1/1/2/3, respectively. Five patients received dose reductions (n=2, levels 2 and 3; n=1, level 1). Twelve patients completed the full cCRT course. One patient (following 12d trametinib) was taken off protocol for an unrelated/unresolved grade 1 event and later experienced grade 5 sepsis/respiratory failure. There was one grade 4 retinal detachment; grade 3 events included skin rash (n=2) and ventricular dysfunction, pneumonitis, pain, fatigue, and diarrhea (n=1 each). The final dose selected by the TiTE-CRM of trametinib was 1.5 mg. Pharmacokinetic profiles were elucidated and extensively described. At median follow-up of 70 months, median PFS was 11 months and median OS was 38 months. CONCLUSIONS: The MTD for trametinib when combined with cCRT is 1.5 mg, with encouraging preliminary outcomes. This combination merits further study to combine with consolidation durvalumab in non-metastatic KRAS mutant NSCLC.
OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung cancer (NSCLC). METHODS: Patients received cCRT (carboplatin/paclitaxel and 60 Gy/30 fractions radiotherapy); oral trametinib (7 days/week) commenced on day 1 and completed on the final day of radiotherapy. Dose-finding of trametinib was done using the time-to-event continual reassessment method (TiTE-CRM); dose levels were 0.5mg (level -1), 1mg (initial, level 1), 1.5mg (level 2), and 2mg (level 3). Progression-free (PFS) and overall survival (OS) times were also recorded. RESULTS: Fifteen patients (stage III, variety of KRAS mutations) were treated, with 1/5/4/5 at dose levels -1/1/2/3, respectively. Five patients received dose reductions (n=2, levels 2 and 3; n=1, level 1). Twelve patients completed the full cCRT course. One patient (following 12d trametinib) was taken off protocol for an unrelated/unresolved grade 1 event and later experienced grade 5 sepsis/respiratory failure. There was one grade 4 retinal detachment; grade 3 events included skin rash (n=2) and ventricular dysfunction, pneumonitis, pain, fatigue, and diarrhea (n=1 each). The final dose selected by the TiTE-CRM of trametinib was 1.5 mg. Pharmacokinetic profiles were elucidated and extensively described. At median follow-up of 70 months, median PFS was 11 months and median OS was 38 months. CONCLUSIONS: The MTD for trametinib when combined with cCRT is 1.5 mg, with encouraging preliminary outcomes. This combination merits further study to combine with consolidation durvalumab in non-metastatic KRAS mutant NSCLC.
Authors: David Planchard; Egbert F Smit; Harry J M Groen; Julien Mazieres; Benjamin Besse; Åslaug Helland; Vanessa Giannone; Anthony M D'Amelio; Pingkuan Zhang; Bijoyesh Mookerjee; Bruce E Johnson Journal: Lancet Oncol Date: 2017-09-11 Impact factor: 41.316
Authors: Jong Woo Lee; Yu Zhang; Kyung Jin Eoh; Roshan Sharma; Miguel F Sanmamed; Jenny Wu; Justin Choi; Hee Sun Park; Akiko Iwasaki; Edward Kaftan; Lieping Chen; Vali Papadimitrakopoulou; Roy S Herbst; Ja Seok Koo Journal: J Thorac Oncol Date: 2019-02-13 Impact factor: 15.609
Authors: Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò Journal: Lancet Oncol Date: 2012-11-28 Impact factor: 41.316
Authors: Eun Joo Chung; Aaron P Brown; Hiroaki Asano; Mariana Mandler; William E Burgan; Donna Carter; Kevin Camphausen; Deborah Citrin Journal: Clin Cancer Res Date: 2009-04-14 Impact factor: 12.531
Authors: David Planchard; Benjamin Besse; Harry J M Groen; Pierre-Jean Souquet; Elisabeth Quoix; Christina S Baik; Fabrice Barlesi; Tae Min Kim; Julien Mazieres; Silvia Novello; James R Rigas; Allison Upalawanna; Anthony M D'Amelio; Pingkuan Zhang; Bijoyesh Mookerjee; Bruce E Johnson Journal: Lancet Oncol Date: 2016-06-06 Impact factor: 41.316
Authors: G R Blumenschein; E F Smit; D Planchard; D-W Kim; J Cadranel; T De Pas; F Dunphy; K Udud; M-J Ahn; N H Hanna; J-H Kim; J Mazieres; S-W Kim; P Baas; E Rappold; S Redhu; A Puski; F S Wu; P A Jänne Journal: Ann Oncol Date: 2015-02-26 Impact factor: 32.976
Authors: P A Jänne; I Smith; G McWalter; H Mann; B Dougherty; J Walker; M C M Orr; D R Hodgson; A T Shaw; J R Pereira; G Jeannin; J Vansteenkiste; C H Barrios; F A Franke; L Crinò; P Smith Journal: Br J Cancer Date: 2015-06-30 Impact factor: 7.640
Authors: Jane S Y Sui; Petra Martin; Anna Keogh; Pierre Murchan; Lisa Ryan; Siobhan Nicholson; Sinead Cuffe; Pilib Ó Broin; Stephen P Finn; Gerard J Fitzmaurice; Ronan Ryan; Vincent Young; Steven G Gray Journal: BMC Pulm Med Date: 2022-08-23 Impact factor: 3.320